Vaxart (NASDAQ:VXRT) posted its quarterly earnings results on Friday. The biotechnology company reported ($0.92) EPS for the quarter, MarketWatch Earnings reports. Vaxart had a negative return on equity of 195.55% and a negative net margin of 317.57%. The business had revenue of $0.28 million for the quarter.

Shares of Vaxart stock traded down $0.34 during trading on Friday, reaching $2.64. 183,719 shares of the company’s stock were exchanged, compared to its average volume of 99,802. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.90 and a quick ratio of 2.90. Vaxart has a 1-year low of $2.37 and a 1-year high of $9.46.

WARNING: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at

About Vaxart

Vaxart, Inc, a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines.

Featured Article: Discount Rate

Earnings History for Vaxart (NASDAQ:VXRT)

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with's FREE daily email newsletter.